Boston Scientific (BSX) Stock

$106.11 -0.03 (-0.03%)
Market Cap: $156.39B | NYSE

Boston Scientific Chart


Company Profile

Price: $106.11

Market Cap: $156.39B

Exchange: NYSE

CEO: Mr. Michael F. Mahoney

Sector: Healthcare

Industry: Medical - Devices

Employees: 48.00K

Headquarters: Marlborough, MA

Business Summary

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific News

EMEA Expansion to Support BSX Stock Amid Fierce Competition

Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.

News image

5 Top-Ranked Efficient Stocks to Buy for Solid Gains Amid Volatility

Invest in stocks of EAT, BFST, AZEK, CLS and BSX to tap their high efficiency levels.

News image

What's Behind The 130% Rise In BSX Stock?

Boston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest stock increase may be due to the significant price appreciation ahead of the earnings announcement.

News image

The Zacks Analyst Blog The Procter & Gamble, Boston, ConocoPhillips and Kewaunee Scientific

The Procter & Gamble, Boston, ConocoPhillips and Kewaunee Scientific are included in this Analyst Blog.

News image

Best Momentum Stocks to Buy for February 10th

BSX, ENVA and CFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 10, 2025.

News image

5 Momentum Stocks to Buy for February Amid Volatility

These five stocks have strong momentum for February. These are: APH, BSX, NLY, PNFP, FHN.

News image

New Strong Buy Stocks for February 10th

PFIS, BSX, ENVA, NFG and NLY have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2025.

News image

Boston Scientific (BSX) is a Great Momentum Stock: Should You Buy?

Does Boston Scientific (BSX) have what it takes to be a top stock pick for momentum investors? Let's find out.

News image

Has Boston Scientific (BSX) Outpaced Other Medical Stocks This Year?

Here is how Boston Scientific (BSX) and Alphatec (ATEC) have performed compared to their sector so far this year.

News image

Here's Why Boston Scientific (BSX) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

News image

Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript

Boston Scientific Corporation (NYSE:BSX ) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Company Participants Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO Kenneth Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Frederick Wise - Stifel Joanne Wuensch - Citibank David Roman - Goldman Sachs Travis Steed - Bank of America Patrick Wood - Morgan Stanley Danielle Antalffy - UBS Michael Polark - Wolfe Research Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Joshua Jennings - TD Cowen Chris Pasquale - Nephron Research Operator Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. All participants will be listen-only mode.

News image

Boston Scientific (BSX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

News image

BSX Q4 Earnings & Revenues Top, Stock Falls on Weak Gross Margin

Boston Scientific's fourth-quarter 2024 performance reflects the strength of its core franchises.

News image

Boston Scientific (BSX) Surpasses Q4 Earnings and Revenue Estimates

Boston Scientific (BSX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.55 per share a year ago.

News image

Boston Scientific sees higher-than-expected 2025 profit on strong demand

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

News image

Boston Scientific announces results for fourth quarter and full year 2024

MARLBOROUGH, Mass. , Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent on an organic2 basis, all compared to the prior year period.

News image

Can These 5 MedTech Stocks Hit Earnings Targets This Season?

Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow.

News image

PBH vs. BSX: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

News image

What Analyst Projections for Key Metrics Reveal About Boston Scientific (BSX) Q4 Earnings

Evaluate the expected performance of Boston Scientific (BSX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

News image

Will Cheaper AI Models Like DeepSeek Become a Boon? 3 Stocks to Watch

As costs related to AI models may come down, as is evident from the cheaper DeepSeek model from China, MedTech companies developing AI-based solutions like SYK, BSX and TEM are likely to gain.

News image

BSX Pre-Q4 Earnings: To Buy or Not to Buy Boston Scientific Stock Now?

Boston Scientific is expected to have registered strong growth in the Asia Pacific in the fourth quarter, led by strength in China and Japan.

News image

Boston Scientific (BSX) Earnings Expected to Grow: Should You Buy?

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News image

Boston Scientific (BSX) Increases Despite Market Slip: Here's What You Need to Know

In the closing of the recent trading day, Boston Scientific (BSX) stood at $102.27, denoting a +0.32% change from the preceding trading day.

News image

BSX Stock Rises on Positive Data Announcement at the AF Symposium

Boston Scientific announces favorable study data for its FARAPULSE PFA system and WATCHMAN FLX device at the AF Symposium 2025.

News image

Boston Scientific (BSX) Increases Yet Falls Behind Market: What Investors Need to Know

Boston Scientific (BSX) closed the most recent trading day at $98.66, moving +0.5% from the previous trading session.

News image

Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSEâ„¢ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and efficacy outcomes with the WATCHMAN FLXâ„¢ Left Atrial Appendage Closure Device post cardiac ablation in both concomitant and sequential procedures MARLBOROUGH, Mass. , Jan. 16, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSEâ„¢ Pulsed Field Ablation (PFA) System* and the WATCHMAN FLXâ„¢ Left Atrial Appendage Closure (LAAC) Device, respectively, during a late-breaking science session at AF Symposium 2025.

News image

PBH or BSX: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?

News image

M&A Synergies Drive BSX: Is it Worth Buying the Stock Now?

Boston Scientific's recent acquisitions have added numerous products with immense potential.

News image

Boston Scientific Jumps Ahead of Earnings

Boston Scientific Corporation (BSX) shares rise on acquisitions – earnings due in early February.

News image

Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors

The latest trading day saw Boston Scientific (BSX) settling at $94.61, representing a -0.28% change from its previous close.

News image

Boston Scientific Earnings

This section highlights Boston Scientific's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: April 23, 2025
Time: Before Market
Est. EPS: $0.64
Status: Unconfirmed

Last Earnings Results

Date: February 05, 2025
EPS: $0.70
Est. EPS: $0.66
Revenue: $4.56B

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q4 2024 2025-02-05 $0.66 $0.70
Read Transcript Q3 2024 2024-10-23 $0.59 $0.63
Read Transcript Q2 2024 2024-07-24 $0.58 $0.62
Read Transcript Q1 2024 2024-04-24 $0.51 $0.56
Read Transcript Q4 2023 2024-01-31 $0.51 $0.55
Read Transcript Q3 2023 2023-10-26 $0.48 $0.50
Read Transcript Q2 2023 2023-07-27 $0.49 $0.53
Read Transcript Q1 2023 2023-04-26 $0.43 $0.47

Financial Statements

Access annual & quarterly financial statements for Boston Scientific, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Revenue $14.24B $12.68B $11.89B $9.91B $10.73B
Cost of Revenue $4.34B $4.00B $3.76B $3.51B $3.18B
Gross Profit $9.89B $8.68B $8.13B $6.40B $7.55B
Gross Profit Ratio 69.49% 68.44% 68.37% 64.59% 70.37%
Research and Development Expenses $1.41B $1.32B $1.20B $1.14B $1.17B
General and Administrative Expenses $- $- $- $- $-
Selling and Marketing Expenses $- $- $- $- $-
Selling General and Administrative Expenses $5.19B $4.52B $4.36B $3.79B $3.94B
Other Expenses $948.00M $803.00M $741.00M $789.00M $699.00M
Operating Expenses $7.55B $6.65B $6.30B $5.72B $5.81B
Cost and Expenses $11.90B $10.65B $10.06B $9.23B $8.99B
Interest Income $22.00M $10.00M $4.00M $3.00M $30.00M
Interest Expense $265.00M $470.00M $341.00M $361.00M $473.00M
Depreciation and Amortization $1.20B $1.14B $1.09B $1.12B $1.01B
EBITDA $3.45B $2.74B $2.52B $1.51B $2.21B
EBITDA Ratio 24.25% 22.08% 23.42% 18.49% 19.39%
Operating Income $2.34B $1.65B $2.04B $1.04B $1.52B
Operating Income Ratio 16.45% 13.00% 17.19% 10.53% 14.14%
Total Other Income Expenses Net $-358.00M $-508.00M $-123.00M $-1.12B $-831.00M
Income Before Tax $1.99B $1.14B $1.08B $-138.00M $687.00M
Income Before Tax Ratio 13.94% 9.00% 9.05% -1.39% 6.40%
Income Tax Expense $393.00M $443.00M $36.00M $2.00M $-4.01B
Net Income $1.59B $698.00M $1.04B $-140.00M $4.70B
Net Income Ratio 11.19% 5.50% 8.76% -1.41% 43.78%
EPS $1.08 $0.45 $0.69 $-0.10 $3.38
EPS Diluted $1.07 $0.45 $0.69 $-0.10 $3.33
Weighted Average Shares Outstanding 1.45B 1.43B 1.42B 1.42B 1.39B
Weighted Average Shares Outstanding Diluted 1.46B 1.44B 1.43B 1.42B 1.41B
SEC Filing Source Source Source Source Source


Income Statement Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Revenue $4.21B $4.12B $3.86B $3.73B $3.53B $3.60B $3.39B $3.24B $3.17B $3.24B $3.03B $3.13B $2.93B $3.08B $2.75B $2.71B $2.66B $2.00B $2.54B $2.90B
Cost of Revenue $1.31B $1.53B $1.21B $1.15B $1.11B $1.07B $1.04B $1.02B $990.00M $1.02B $967.00M $982.00M $914.00M $957.00M $906.00M $1.01B $881.00M $799.00M $818.00M $868.00M
Gross Profit $2.90B $2.58B $2.65B $2.58B $2.42B $2.53B $2.35B $2.22B $2.18B $2.22B $2.06B $2.15B $2.02B $2.12B $1.85B $1.69B $1.78B $1.20B $1.73B $2.04B
Gross Profit Ratio 68.83% 62.74% 68.65% 69.21% 68.47% 70.27% 69.31% 68.41% 68.77% 68.50% 68.04% 68.60% 68.83% 68.90% 67.08% 62.56% 66.87% 60.11% 67.83% 70.12%
Research and Development Expenses $407.00M $383.00M $366.00M $363.00M $356.00M $359.00M $337.00M $330.00M $339.00M $335.00M $319.00M $320.00M $310.00M $298.00M $276.00M $286.00M $315.00M $242.00M $300.00M $309.00M
General and Administrative Expenses $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $1.03B $984.00M $798.00M $978.00M $1.09B
Selling and Marketing Expenses $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Selling General and Administrative Expenses $1.56B $1.45B $1.36B $1.38B $1.24B $1.35B $1.22B $1.16B $1.13B $1.17B $1.06B $1.15B $1.07B $1.12B $1.02B $1.03B $984.00M $798.00M $978.00M $1.09B
Other Expenses $195.00M $-9.00M $-224.00M $64.00M $-18.00M $-18.00M $214.00M $199.00M $202.00M $204.00M $198.00M $26.00M $181.00M $-26.00M $37.00M $352.00M $64.00M $-18.00M $-36.00M $-37.00M
Operating Expenses $2.16B $1.84B $1.95B $1.96B $1.81B $1.92B $1.77B $1.69B $1.67B $1.70B $1.58B $1.67B $1.56B $1.60B $1.48B $1.51B $1.50B $1.24B $1.48B $1.60B
Cost and Expenses $3.48B $3.37B $3.16B $3.11B $2.92B $2.99B $2.81B $2.72B $2.66B $2.73B $2.54B $2.65B $2.47B $2.56B $2.39B $2.52B $2.38B $2.04B $2.30B $2.47B
Interest Income $- $- $- $22.00M $66.00M $70.00M $65.00M $4.00M $1.00M $1.00M $4.00M $1.00M $1.00M $1.00M $1.00M $- $1.00M $- $1.00M $1.00M
Interest Expense $79.00M $77.00M $69.00M $65.00M $66.00M $70.00M $65.00M $64.00M $63.00M $64.00M $279.00M $87.00M $86.00M $86.00M $82.00M $96.00M $86.00M $91.00M $88.00M $179.00M
Depreciation and Amortization $306.00M $311.00M $304.00M $313.00M $301.00M $298.00M $285.00M $294.00M $284.00M $284.00M $274.00M $290.00M $272.00M $263.00M $268.00M $194.00M $282.00M $275.00M $277.00M $201.00M
EBITDA $1.05B $812.00M $984.00M $883.00M $976.00M $795.00M $796.00M $757.00M $593.00M $692.00M $725.00M $498.00M $841.00M $500.00M $682.00M $597.00M $145.00M $191.00M $392.00M $374.00M
EBITDA Ratio 25.04% 25.68% 25.96% 27.28% 22.71% 22.17% 21.95% 24.21% 20.79% 21.86% 21.45% 22.35% 28.10% 21.90% 21.40% 27.07% 20.46% 7.19% 16.16% 20.62%
Operating Income $733.00M $747.00M $693.00M $584.00M $693.00M $514.00M $552.00M $586.00M $358.00M $423.00M $466.00M $180.00M $387.00M $262.00M $370.00M $-8.00M $-205.00M $-71.00M $146.00M $210.00M
Operating Income Ratio 17.42% 18.13% 17.97% 15.68% 19.65% 14.28% 16.29% 18.08% 11.29% 13.04% 15.40% 5.76% 13.20% 8.51% 13.44% -0.30% -7.71% -3.54% 5.74% 7.23%
Total Other Income Expenses Net $-64.00M $-100.00M $-67.00M $-79.00M $-83.00M $-88.00M $-108.00M $-53.00M $-113.00M $-78.00M $-310.00M $-61.00M $96.00M $-113.00M $-45.00M $-386.00M $-22.00M $-110.00M $-124.00M $-216.00M
Income Before Tax $669.00M $420.00M $608.00M $505.00M $610.00M $426.00M $444.00M $396.00M $245.00M $345.00M $156.00M $120.00M $483.00M $149.00M $325.00M $248.00M $-227.00M $-181.00M $22.00M $-6.00M
Income Before Tax Ratio 15.89% 10.19% 15.77% 13.56% 17.30% 11.84% 13.10% 12.21% 7.73% 10.64% 5.16% 3.84% 16.47% 4.84% 11.81% 9.16% -8.54% -9.04% 0.87% -0.21%
Income Tax Expense $200.00M $98.00M $115.00M $1.00M $105.00M $156.00M $131.00M $256.00M $57.00M $85.00M $45.00M $26.00M $64.00M $-37.00M $-16.00M $96.00M $-72.00M $-33.00M $12.00M $-4.00B
Net Income $468.00M $324.00M $492.00M $505.00M $504.00M $270.00M $314.00M $140.00M $174.00M $246.00M $96.00M $82.00M $405.00M $172.00M $327.00M $152.00M $-155.00M $-147.00M $11.00M $4.00B
Net Income Ratio 11.12% 7.86% 12.76% 13.56% 14.29% 7.50% 9.27% 4.32% 5.49% 7.58% 3.17% 2.62% 13.81% 5.59% 11.88% 5.61% -5.83% -7.34% 0.43% 137.56%
EPS $0.32 $0.22 $0.34 $0.34 $0.34 $0.18 $0.21 $0.09 $0.12 $0.17 $0.07 $0.07 $0.29 $0.13 $0.24 $0.11 $-0.11 $-0.11 $0.01 $2.87
EPS Diluted $0.32 $0.22 $0.33 $0.34 $0.34 $0.18 $0.21 $0.09 $0.12 $0.17 $0.07 $0.07 $0.29 $0.13 $0.24 $0.11 $-0.11 $-0.10 $0.01 $2.83
Weighted Average Shares Outstanding 1.47B 1.47B 1.47B 1.47B 1.46B 1.45B 1.44B 1.43B 1.43B 1.43B 1.43B 1.43B 1.42B 1.42B 1.42B 1.43B 1.41B 1.38B 1.40B 1.39B
Weighted Average Shares Outstanding Diluted 1.49B 1.48B 1.48B 1.48B 1.48B 1.46B 1.45B 1.44B 1.44B 1.44B 1.44B 1.44B 1.44B 1.43B 1.43B 1.44B 1.43B 1.41B 1.41B 1.41B
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Cash and Cash Equivalents $865.00M $928.00M $1.93B $1.73B $217.00M
Short Term Investments $- $- $- $- $-
Cash and Short Term Investments $865.00M $928.00M $1.93B $1.73B $217.00M
Net Receivables $2.23B $1.97B $1.78B $1.53B $1.83B
Inventory $2.48B $1.87B $1.61B $1.35B $1.58B
Other Current Assets $937.00M $995.00M $1.00B $2.08B $1.07B
Total Current Assets $6.51B $5.76B $6.32B $6.69B $4.70B
Property Plant Equipment Net $3.30B $2.83B $2.69B $2.54B $2.42B
Goodwill $14.39B $12.92B $11.99B $9.95B $10.18B
Intangible Assets $6.00B $5.90B $6.12B $5.92B $7.89B
Goodwill and Intangible Assets $20.39B $18.82B $18.11B $15.87B $18.06B
Long Term Investments $413.00M $407.00M $412.00M $918.00M $458.00M
Tax Assets $3.84B $3.94B $4.14B $4.21B $4.20B
Other Non-Current Assets $680.00M $707.00M $563.00M $545.00M $735.00M
Total Non-Current Assets $28.62B $26.71B $25.91B $24.08B $25.87B
Other Assets $- $- $2.00M $3.00M $-
Total Assets $35.14B $32.47B $32.23B $30.78B $30.57B
Account Payables $942.00M $862.00M $794.00M $513.00M $542.00M
Short Term Debt $531.00M $20.00M $261.00M $13.00M $1.42B
Tax Payables $220.00M $232.00M $209.00M $158.00M $265.00M
Deferred Revenue $266.00M $220.00M $208.00M $138.00M $144.00M
Other Current Liabilities $2.97B $2.47B $2.80B $2.86B $2.50B
Total Current Liabilities $4.93B $3.80B $4.27B $3.68B $4.87B
Long Term Debt $8.96B $9.26B $9.19B $9.53B $8.87B
Deferred Revenue Non-Current $311.00M $289.00M $276.00M $257.00M $1.20B
Deferred Tax Liabilities Non-Current $134.00M $144.00M $310.00M $330.00M $595.00M
Other Non-Current Liabilities $1.27B $1.40B $1.55B $1.66B $2.36B
Total Non-Current Liabilities $10.67B $11.09B $11.33B $11.77B $11.82B
Other Liabilities $- $- $- $- $-
Total Liabilities $15.61B $14.90B $15.61B $15.45B $16.69B
Preferred Stock $- $- $- $- $-
Common Stock $17.00M $17.00M $17.00M $17.00M $16.00M
Retained Earnings $819.00M $-750.00M $-1.39B $-2.38B $-2.25B
Accumulated Other Comprehensive Income Loss $49.00M $269.00M $263.00M $207.00M $270.00M
Other Total Stockholders Equity $18.40B $18.04B $17.73B $17.48B $15.84B
Total Stockholders Equity $19.28B $17.57B $16.62B $15.33B $13.88B
Total Equity $19.53B $17.57B $16.62B $15.33B $13.88B
Total Liabilities and Stockholders Equity $34.89B $32.47B $32.23B $30.78B $30.57B
Minority Interest $248.00M $- $- $- $-
Total Liabilities and Total Equity $34.89B $32.47B $32.23B $30.78B $30.57B
Total Investments $413.00M $407.00M $412.00M $918.00M $458.00M
Total Debt $9.49B $9.28B $9.45B $9.54B $10.28B
Net Debt $8.63B $8.35B $7.53B $7.80B $10.06B


Balance Sheet Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Cash and Cash Equivalents $2.50B $2.99B $2.33B $865.00M $952.00M $426.00M $570.00M $928.00M $338.00M $276.00M $325.00M $1.93B $1.95B $2.67B $2.02B $1.73B $2.02B $1.72B $370.00M $217.00M
Short Term Investments $- $- $1.73B $- $- $- $- $- $- $- $7.00M $- $- $- $- $- $- $- $- $-
Cash and Short Term Investments $2.50B $2.99B $2.33B $865.00M $952.00M $426.00M $570.00M $928.00M $338.00M $276.00M $325.00M $1.93B $1.95B $2.67B $2.02B $1.73B $2.02B $1.72B $370.00M $217.00M
Net Receivables $2.50B $2.40B $2.30B $2.23B $2.10B $2.13B $2.08B $1.97B $1.87B $1.92B $1.87B $1.78B $1.67B $1.68B $1.63B $1.53B $1.60B $1.46B $1.70B $1.83B
Inventory $2.75B $2.61B $2.56B $2.48B $2.40B $2.25B $2.05B $1.87B $1.79B $1.75B $1.74B $1.61B $1.60B $1.43B $1.41B $1.35B $1.47B $1.52B $1.63B $1.58B
Other Current Assets $1.00B $1.07B $991.00M $937.00M $1.05B $1.08B $1.01B $995.00M $1.15B $1.14B $1.14B $1.00B $1.01B $978.00M $1.05B $2.08B $1.07B $1.11B $1.12B $1.07B
Total Current Assets $8.76B $8.99B $8.19B $6.51B $6.50B $5.89B $5.70B $5.76B $5.14B $5.08B $5.07B $6.32B $6.23B $6.76B $6.10B $6.69B $6.16B $5.80B $4.82B $4.70B
Property Plant Equipment Net $3.50B $3.37B $3.33B $3.30B $3.08B $2.98B $2.88B $2.83B $2.66B $2.65B $2.69B $2.69B $2.52B $2.49B $2.46B $2.54B $2.38B $2.39B $2.42B $2.42B
Goodwill $15.03B $14.40B $14.36B $14.39B $13.61B $13.66B $13.27B $12.92B $12.85B $12.88B $12.95B $11.99B $11.82B $10.87B $10.87B $9.95B $10.14B $10.10B $10.10B $10.18B
Intangible Assets $5.75B $5.42B $5.84B $6.00B $5.85B $6.06B $6.06B $5.90B $6.06B $6.35B $6.58B $6.12B $6.23B $5.79B $5.99B $5.92B $6.80B $7.16B $7.39B $7.89B
Goodwill and Intangible Assets $20.79B $19.81B $20.20B $20.39B $19.46B $19.72B $19.33B $18.82B $18.91B $19.23B $19.53B $18.11B $18.05B $16.66B $16.86B $15.87B $16.93B $17.26B $17.49B $18.06B
Long Term Investments $532.00M $589.00M $429.00M $413.00M $427.00M $421.00M $385.00M $407.00M $381.00M $376.00M $399.00M $412.00M $434.00M $616.00M $643.00M $918.00M $567.00M $467.00M $437.00M $458.00M
Tax Assets $3.82B $3.80B $3.79B $3.84B $3.84B $3.87B $3.90B $3.94B $4.02B $4.06B $4.10B $4.14B $4.05B $4.04B $4.17B $4.21B $4.17B $4.18B $4.16B $4.20B
Other Non-Current Assets $684.00M $546.00M $737.00M $679.00M $732.00M $728.00M $697.00M $707.00M $834.00M $791.00M $552.00M $563.00M $594.00M $603.00M $664.00M $545.00M $636.00M $717.00M $775.00M $735.00M
Total Non-Current Assets $29.32B $28.12B $28.48B $28.62B $27.54B $27.72B $27.19B $26.71B $26.80B $27.10B $27.27B $25.91B $25.65B $24.41B $24.80B $24.08B $24.68B $25.02B $25.29B $25.87B
Other Assets $- $- $1.00M $1.00M $- $-1.00M $-2.00M $- $-1.00M $3.00M $-2.00M $2.00M $- $1.00M $- $3.00M $1.00M $-2.00M $-1.00M $-
Total Assets $38.08B $37.11B $36.67B $35.14B $34.04B $33.60B $32.89B $32.47B $31.95B $32.19B $32.34B $32.23B $31.88B $31.17B $30.90B $30.78B $30.84B $30.82B $30.11B $30.57B
Account Payables $907.00M $906.00M $921.00M $942.00M $929.00M $899.00M $868.00M $862.00M $803.00M $732.00M $696.00M $794.00M $674.00M $689.00M $615.00M $513.00M $452.00M $408.00M $605.00M $542.00M
Short Term Debt $1.65B $1.58B $1.08B $531.00M $513.00M $559.00M $510.00M $20.00M $20.00M $170.00M $238.00M $261.00M $261.00M $262.00M $13.00M $13.00M $11.00M $254.00M $1.00B $1.42B
Tax Payables $332.00M $224.00M $257.00M $220.00M $352.00M $400.00M $281.00M $232.00M $234.00M $257.00M $459.00M $209.00M $113.00M $121.00M $151.00M $158.00M $37.00M $193.00M $246.00M $265.00M
Deferred Revenue $290.00M $284.00M $280.00M $266.00M $246.00M $242.00M $231.00M $220.00M $216.00M $222.00M $212.00M $208.00M $160.00M $141.00M $139.00M $138.00M $147.00M $143.00M $141.00M $144.00M
Other Current Liabilities $2.73B $2.58B $2.37B $2.97B $2.54B $2.46B $2.19B $2.47B $2.28B $2.50B $2.67B $2.80B $2.81B $2.86B $2.48B $2.86B $2.65B $2.11B $1.98B $2.50B
Total Current Liabilities $5.91B $5.58B $4.92B $4.93B $4.58B $4.56B $4.08B $3.80B $3.55B $3.88B $4.28B $4.27B $4.02B $4.07B $3.39B $3.68B $3.30B $3.11B $3.98B $4.87B
Long Term Debt $9.61B $9.36B $9.92B $8.96B $8.79B $8.89B $8.86B $9.26B $8.91B $9.16B $9.45B $9.19B $9.20B $9.20B $9.44B $9.53B $9.33B $9.54B $9.59B $8.87B
Deferred Revenue Non-Current $328.00M $316.00M $314.00M $311.00M $301.00M $295.00M $290.00M $289.00M $278.00M $279.00M $279.00M $276.00M $296.00M $283.00M $264.00M $257.00M $6.00M $251.00M $251.00M $1.20B
Deferred Tax Liabilities Non-Current $138.00M $132.00M $132.00M $134.00M $91.00M $135.00M $210.00M $144.00M $278.00M $265.00M $261.00M $310.00M $274.00M $115.00M $336.00M $330.00M $522.00M $585.00M $589.00M $595.00M
Other Non-Current Liabilities $1.14B $1.12B $1.22B $1.27B $1.16B $1.23B $1.34B $1.40B $1.29B $1.35B $1.34B $1.55B $1.62B $1.55B $1.75B $1.66B $2.13B $1.73B $1.90B $2.36B
Total Non-Current Liabilities $11.21B $10.92B $11.59B $10.67B $10.34B $10.55B $10.70B $11.09B $10.76B $11.05B $11.33B $11.33B $11.39B $11.15B $11.79B $11.77B $11.98B $12.10B $12.33B $11.82B
Other Liabilities $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities $17.12B $16.50B $16.50B $15.61B $14.91B $15.12B $14.78B $14.90B $14.31B $14.94B $15.60B $15.61B $15.41B $15.23B $15.18B $15.45B $15.28B $15.21B $16.31B $16.69B
Preferred Stock $- $- $18.21B $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $17.00M $16.00M $16.00M
Retained Earnings $2.11B $1.64B $1.31B $819.00M $315.00M $-189.00M $-450.00M $-750.00M $-876.00M $-1.05B $-1.30B $-1.39B $-1.47B $-1.88B $-2.05B $-2.38B $-2.57B $-2.40B $-2.25B $-2.25B
Accumulated Other Comprehensive Income Loss $-128.00M $164.00M $132.00M $49.00M $231.00M $208.00M $178.00M $269.00M $532.00M $433.00M $222.00M $263.00M $238.00M $237.00M $254.00M $207.00M $151.00M $131.00M $168.00M $270.00M
Other Total Stockholders Equity $18.71B $18.55B $18.46B $18.40B $18.32B $18.19B $18.11B $18.31B $17.97B $17.85B $17.79B $17.73B $17.68B $17.57B $17.50B $17.48B $17.97B $17.87B $15.87B $15.84B
Total Stockholders Equity $20.71B $20.37B $19.93B $19.28B $18.89B $18.23B $17.85B $17.57B $17.64B $17.25B $16.73B $16.62B $16.46B $15.94B $15.72B $15.33B $15.56B $15.62B $13.80B $13.88B
Total Equity $20.96B $20.61B $20.17B $19.53B $19.13B $18.48B $18.11B $17.57B $17.64B $17.25B $16.73B $16.62B $16.46B $15.94B $15.72B $15.33B $15.56B $15.62B $13.80B $13.88B
Total Liabilities and Stockholders Equity $38.08B $37.11B $36.43B $34.89B $33.80B $33.60B $32.89B $32.47B $31.95B $32.19B $32.34B $32.23B $31.88B $31.17B $30.90B $30.78B $30.84B $30.82B $30.11B $30.57B
Minority Interest $248.00M $238.00M $242.00M $248.00M $243.00M $259.00M $259.00M $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities and Total Equity $38.08B $37.11B $36.43B $34.89B $33.80B $33.60B $32.89B $32.47B $31.95B $32.19B $32.34B $32.23B $31.88B $31.17B $30.90B $30.78B $30.84B $30.82B $30.11B $30.57B
Total Investments $532.00M $589.00M $1.73B $413.00M $427.00M $421.00M $385.00M $407.00M $381.00M $376.00M $406.00M $412.00M $434.00M $616.00M $643.00M $918.00M $567.00M $467.00M $437.00M $458.00M
Total Debt $11.26B $10.94B $11.00B $9.49B $9.30B $9.45B $9.37B $9.28B $8.93B $9.33B $9.68B $9.45B $9.46B $9.46B $9.44B $9.54B $9.33B $9.79B $10.60B $10.28B
Net Debt $8.76B $7.95B $8.67B $8.63B $8.35B $9.03B $8.79B $8.35B $8.60B $9.05B $9.36B $7.53B $7.51B $6.79B $7.43B $7.80B $7.31B $8.06B $10.23B $10.06B

Annual Cash Flow

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Net Income $1.59B $698.00M $1.04B $-82.00M $4.70B
Depreciation and Amortization $1.20B $1.14B $1.09B $1.12B $1.01B
Deferred Income Tax $-1.00M $-63.00M $-124.00M $-82.00M $-4.30B
Stock Based Compensation $233.00M $220.00M $194.00M $170.00M $157.00M
Change in Working Capital $-770.00M $-1.00B $-351.00M $42.00M $-282.00M
Accounts Receivables $-238.00M $-220.00M $-279.00M $335.00M $-130.00M
Inventory $-660.00M $-321.00M $-346.00M $-65.00M $-290.00M
Accounts Payables $118.00M $-255.00M $408.00M $88.00M $111.00M
Other Working Capital $10.00M $-209.00M $-134.00M $-316.00M $27.00M
Other Non Cash Items $253.00M $540.00M $17.00M $337.00M $551.00M
Net Cash Provided by Operating Activities $2.50B $1.53B $1.87B $1.51B $1.84B
Investments in Property Plant and Equipment $-711.00M $-612.00M $-554.00M $-376.00M $-461.00M
Acquisitions Net $-1.81B $-1.54B $-1.43B $12.00M $-4.29B
Purchases of Investments $- $-24.00M $96.00M $-146.00M $-348.00M
Sales Maturities of Investments $- $56.00M $294.00M $12.00M $59.00M
Other Investing Activities $-52.00M $106.00M $-1.00M $87.00M $1.00M
Net Cash Used for Investing Activities $-2.57B $-2.01B $-1.60B $-411.00M $-5.04B
Debt Repayment $-4.00M $-165.00M $- $-999.00M $2.79B
Common Stock Issued $182.00M $- $110.00M $975.00M $123.00M
Common Stock Repurchased $182.00M $136.00M $110.00M $-535.00M $-
Dividends Paid $-28.00M $-55.00M $-55.00M $-28.00M $-
Other Financing Activities $37.00M $-464.00M $-40.00M $880.00M $179.00M
Net Cash Used Provided by Financing Activities $5.00M $-548.00M $-95.00M $293.00M $2.97B
Effect of Forex Changes on Cash $-4.00M $-9.00M $-6.00M $-2.00M $10.00M
Net Change in Cash $-71.00M $-1.04B $173.00M $1.39B $-222.00M
Cash at End of Period $1.05B $1.13B $2.17B $2.00B $607.00M
Cash at Beginning of Period $1.13B $2.17B $2.00B $607.00M $829.00M
Operating Cash Flow $2.50B $1.53B $1.87B $1.51B $1.84B
Capital Expenditure $-800.00M $-612.00M $-554.00M $-376.00M $-461.00M
Free Cash Flow $1.70B $914.00M $1.32B $1.13B $1.38B

Cash Flow Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Net Income $700.00M $324.00M $493.00M $504.00M $504.00M $270.00M $314.00M $140.00M $188.00M $260.00M $110.00M $95.00M $419.00M $186.00M $341.00M $210.00M $-155.00M $-148.00M $11.00M $4.00B
Depreciation and Amortization $636.00M $311.00M $304.00M $313.00M $300.00M $298.00M $285.00M $294.00M $284.00M $284.00M $274.00M $290.00M $272.00M $263.00M $268.00M $289.00M $282.00M $275.00M $277.00M $293.00M
Deferred Income Tax $-11.00M $-10.00M $31.00M $73.00M $-29.00M $-64.00M $19.00M $7.00M $23.00M $-18.00M $-75.00M $-75.00M $39.00M $-87.00M $-1.00M $- $-28.00M $8.00M $7.00M $-
Stock Based Compensation $-61.00M $195.00M $63.00M $59.00M $59.00M $60.00M $55.00M $55.00M $58.00M $55.00M $52.00M $49.00M $51.00M $47.00M $47.00M $42.00M $40.00M $46.00M $42.00M $157.00M
Change in Working Capital $523.00M $-209.00M $-743.00M $-57.00M $-176.00M $-14.00M $-523.00M $334.00M $-304.00M $-353.00M $-682.00M $-35.00M $-211.00M $248.00M $-353.00M $-117.00M $320.00M $18.00M $-580.00M $-393.00M
Accounts Receivables $-175.00M $-114.00M $-114.00M $-74.00M $-3.00M $-75.00M $-86.00M $-44.00M $-14.00M $-96.00M $-66.00M $-148.00M $14.00M $-28.00M $-117.00M $93.00M $-123.00M $204.00M $161.00M $-130.00M
Inventory $-89.00M $-95.00M $-124.00M $-59.00M $-202.00M $-214.00M $-185.00M $-46.00M $-95.00M $-72.00M $-108.00M $-31.00M $-215.00M $15.00M $-115.00M $-64.00M $35.00M $163.00M $-199.00M $-290.00M
Accounts Payables $69.00M $71.00M $-450.00M $23.00M $17.00M $289.00M $-211.00M $335.00M $-141.00M $-81.00M $-368.00M $133.00M $-65.00M $333.00M $7.00M $88.00M $- $- $- $111.00M
Other Working Capital $718.00M $-71.00M $-55.00M $53.00M $12.00M $-14.00M $482.00M $89.00M $-54.00M $-104.00M $-140.00M $144.00M $55.00M $-72.00M $-128.00M $-146.00M $408.00M $-349.00M $-542.00M $27.00M
Other Non Cash Items $-785.00M $1.16B $14.00M $65.00M $40.00M $108.00M $40.00M $-23.00M $221.00M $79.00M $263.00M $154.00M $-105.00M $-14.00M $-18.00M $249.00M $184.00M $70.00M $166.00M $-3.36B
Net Cash Provided by Operating Activities $1.00B $813.00M $164.00M $957.00M $698.00M $658.00M $190.00M $807.00M $470.00M $307.00M $-58.00M $478.00M $465.00M $643.00M $284.00M $673.00M $643.00M $269.00M $-77.00M $692.00M
Investments in Property Plant and Equipment $-179.00M $-155.00M $-245.00M $-267.00M $-206.00M $-206.00M $-121.00M $-200.00M $-172.00M $-105.00M $-131.00M $-266.00M $-107.00M $-106.00M $-75.00M $-159.00M $-150.00M $-95.00M $-102.00M $-186.00M
Acquisitions Net $-1.13B $-48.00M $-47.00M $-793.00M $1.00M $-643.00M $-375.00M $-5.00M $-71.00M $1.00M $-1.47B $-219.00M $-1.31B $3.00M $95.00M $-15.00M $- $12.00M $- $-90.00M
Purchases of Investments $- $-73.00M $-66.00M $-28.00M $-16.00M $-63.00M $-10.00M $15.00M $-22.00M $1.00M $-15.00M $51.00M $-21.00M $-17.00M $-13.00M $-16.00M $-101.00M $-27.00M $-2.00M $83.00M
Sales Maturities of Investments $- $- $- $28.00M $15.00M $2.00M $10.00M $70.00M $22.00M $-2.00M $32.00M $-50.00M $207.00M $-10.00M $25.00M $- $- $1.00M $- $-
Other Investing Activities $-121.00M $4.00M $-1.00M $7.00M $9.00M $70.00M $12.00M $-63.00M $18.00M $76.00M $11.00M $74.00M $22.00M $133.00M $39.00M $28.00M $122.00M $50.00M $28.00M $54.00M
Net Cash Used for Investing Activities $-1.43B $-271.00M $-285.00M $-1.05B $-197.00M $-840.00M $-484.00M $-183.00M $-225.00M $-29.00M $-1.57B $-461.00M $-1.21B $-133.00M $71.00M $-147.00M $-129.00M $-59.00M $-76.00M $-49.00M
Debt Repayment $22.00M $- $1.62B $- $-41.00M $37.00M $- $- $-155.00M $-11.00M $60.00M $- $- $- $- $-260.00M $-250.00M $-835.00M $346.00M $-990.00M
Common Stock Issued $96.00M $26.00M $80.00M $17.00M $75.00M $27.00M $63.00M $19.00M $59.00M $6.00M $- $8.00M $64.00M $20.00M $- $- $- $933.00M $42.00M $10.00M
Common Stock Repurchased $- $- $80.00M $119.00M $- $- $63.00M $136.00M $- $- $52.00M $110.00M $- $- $18.00M $-535.00M $- $- $- $-
Dividends Paid $-23.00M $- $- $- $- $-14.00M $-14.00M $-13.00M $-14.00M $-14.00M $-14.00M $-13.00M $-14.00M $-14.00M $-14.00M $-14.00M $-14.00M $- $- $-
Other Financing Activities $1.58B $24.00M $-47.00M $15.00M $57.00M $20.00M $-55.00M $14.00M $-89.00M $-325.00M $-104.00M $5.00M $20.00M $16.00M $-81.00M $-10.00M $-44.00M $1.01B $-132.00M $256.00M
Net Cash Used Provided by Financing Activities $1.68B $24.00M $1.57B $15.00M $16.00M $43.00M $-69.00M $1.00M $-199.00M $-344.00M $-6.00M $-8.00M $6.00M $2.00M $-95.00M $-819.00M $-249.00M $1.10B $256.00M $-724.00M
Effect of Forex Changes on Cash $-2.00M $-1.00M $-7.00M $4.00M $-5.00M $-3.00M $- $3.00M $-6.00M $-6.00M $-1.00M $-1.00M $-3.00M $1.00M $-3.00M $6.00M $1.00M $1.00M $-9.00M $12.00M
Net Change in Cash $-413.00M $566.00M $1.44B $-77.00M $512.00M $-143.00M $-363.00M $629.00M $39.00M $-71.00M $-1.64B $9.00M $-739.00M $645.00M $258.00M $-287.00M $266.00M $1.32B $93.00M $-69.00M
Cash at End of Period $2.65B $2.99B $2.50B $1.05B $1.13B $620.00M $763.00M $1.13B $497.00M $458.00M $529.00M $2.17B $2.16B $2.90B $2.25B $2.00B $2.28B $2.02B $700.00M $607.00M
Cash at Beginning of Period $3.06B $2.42B $1.05B $1.13B $620.00M $763.00M $1.13B $497.00M $458.00M $529.00M $2.17B $2.16B $2.90B $2.25B $2.00B $2.28B $2.02B $700.00M $607.00M $676.00M
Operating Cash Flow $1.00B $813.00M $164.00M $957.00M $698.00M $658.00M $190.00M $807.00M $470.00M $307.00M $-58.00M $478.00M $465.00M $643.00M $284.00M $673.00M $643.00M $269.00M $-77.00M $692.00M
Capital Expenditure $-304.00M $-155.00M $-245.00M $-267.00M $-206.00M $-206.00M $-121.00M $-200.00M $-172.00M $-105.00M $-131.00M $-266.00M $-107.00M $-106.00M $-75.00M $-159.00M $-150.00M $-95.00M $-102.00M $-186.00M
Free Cash Flow $698.00M $658.00M $-81.00M $690.00M $492.00M $452.00M $69.00M $607.00M $298.00M $202.00M $-189.00M $212.00M $358.00M $537.00M $209.00M $514.00M $493.00M $174.00M $-179.00M $506.00M


Boston Scientific Stock Forecast

Analyst ratings, price targets, and earnings estimates for BSX.

BSX Analyst Ratings

Strong Buy

Buy
14
Hold
3
Sell
0

Based on 17 analysts in the past 3 months

BSX Stock 12 Month Forecast

$105.33

â–¼ (-0.74% Downside)
Highest Price Target
$ (0.0%)
Average Price Target
$105.33 (-0.7%)
Lowest Price Target
$ (0.0%)

Based on 3 analysts in the last 3 months

Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High $19.29B
Average $19.15B
Low $18.76B
21 analysts
Net Income Estimates
High $4.26B
Average $4.18B
Low $4.11B
21 analysts
EPS Estimates
High $2.91
Average $2.86
Low $2.81
18 analysts
Revenue Estimates
High $21.66B
Average $21.10B
Low $20.62B
24 analysts
Net Income Estimates
High $4.89B
Average $4.73B
Low $4.56B
24 analysts
EPS Estimates
High $3.34
Average $3.26
Low $3.12
18 analysts
Revenue Estimates
High $23.13B
Average $23.11B
Low $23.09B
21 analysts
Net Income Estimates
High $6.69B
Average $4.03B
Low $3.82B
21 analysts
EPS Estimates
High $4.57
Average $3.67
Low $2.61
7 analysts
Revenue Estimates
High $25.55B
Average $25.11B
Low $24.52B
17 analysts
Net Income Estimates
High $6.18B
Average $6.04B
Low $5.86B
17 analysts
EPS Estimates
High $4.22
Average $4.13
Low $4.00
4 analysts
Revenue Estimates
High $27.57B
Average $27.10B
Low $26.46B
10 analysts
Net Income Estimates
High $6.63B
Average $6.49B
Low $6.29B
10 analysts
EPS Estimates
High $4.53
Average $4.43
Low $4.30
2 analysts
Latest Price Target Updates
Date Analyst Firm Price Target Price When Posted Upside
Feb 03, 2025 Matt O'Brien Piper Sandler $115.00 $103.07 11.6%
Jan 02, 2025 Vijay Kumar Evercore ISI $100.00 $89.38 11.9%
Dec 30, 2024 Marie Thibault BTIG $101.00 $89.68 12.6%
Oct 24, 2024 Shagun Singh RBC Capital $98.00 $87.45 12.1%
Oct 24, 2024 Kristen Stewart C.L. King $90.00 $87.45 2.9%
Oct 21, 2024 William Plovanic Canaccord Genuity $98.00 $88.07 11.3%
Oct 18, 2024 Rick Wise Stifel Nicolaus $100.00 $86.42 15.7%
Oct 15, 2024 David Rescott Robert W. Baird $100.00 $87.55 14.2%
Oct 14, 2024 Richard Newitter Truist Financial $100.00 $87.20 14.7%
Sep 19, 2024 Matt O'Brien Piper Sandler $90.00 $84.23 6.9%

Boston Scientific Dividends

Explore Boston Scientific's dividend history, including dividend yield, payout ratio, and historical payments.

Boston Scientific does not currently pay a dividend.

Peers: Medical - Devices

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
SYK Logo
Stryker Corporation
SYK
$146.98B $385.18 $7.86 $45.83 $6.65
ABT Logo
Abbott Laboratories
ABT
$226.54B $130.61 $3.30 $33.35 $4.94
MDT Logo
Medtronic plc
MDT
$119.01B $92.81 $2.77 $28.80 $2.11
DXCM Logo
DexCom, Inc.
DXCM
$34.79B $89.07 $1.40 $88.46 $23.16
EW Logo
Edwards Lifesciences Corporation
EW
$44.94B $76.19 $2.31 $32.99 $6.96
ZBH Logo
Zimmer Biomet Holdings, Inc.
ZBH
$20.01B $100.52 $0.00 $0.00 $0.00
 Logo
$- $ $ $ $
ZIMV Logo
ZimVie Inc.
ZIMV
$362.65M $13.14 $-14.87 $-1.19 $1.15
STE Logo
STERIS plc
STE
$21.55B $219.34 $3.83 $57.73 $3.46
SNN Logo
Smith & Nephew plc
SNN
$11.21B $25.70 $0.30 $45.15 $2.28

Related Metrics

Explore detailed financial metrics and analysis for BSX.

Ownership